Therefore, the AHR pathway is an attractive target for the control of inflammatory skin disease, and topical application of tapinarof, a naturally derived AHR ligand (Smith et al., 2017), has shown promising efficacy in phase II clinical trials for psoriasis and atopic dermatitis (Peppers et al., 2019; Robbins et al., 2019). The gene discussed is AHR; the disease is inflammatory skin disease.